Built for the operating reality of clinical development
CadenceAI starts from the operating reality of emerging biotech: development plans change, regulatory prerequisites move, vendors and sites execute in parallel, contracts evolve, and financial consequences follow.
Company details
Founded in May 2023, CadenceAI builds an AI-native clinical development platform for emerging biotech teams. Cadence Chen serves as CEO, and Tomas Van serves as Advisor.
- Founded
- May 2023
- Contact
- tvan@cadence-ai.com
- Website
- www.cadence-ai.com
Clinical development teams manage a connected program through disconnected tools. The plan lives in timelines and decks; regulatory prerequisites in separate trackers; vendor commitments in SOWs and amendments; site execution in operational systems; financial truth in invoices, accruals, and spreadsheets.
We built CadenceAI around a different question: what if an AI-native system could understand how the whole development program fits together and think alongside the team as it changes? That means connecting milestones and dependencies to vendors, contracts, sites, regulatory commitments, spend, assumptions, and the evidence behind each decision.
The result is a clinical development operating platform designed to give emerging biotech sponsor-side program control now and build a durable intelligence layer around how assets move from development strategy to the clinic over time.
Our mission
Give emerging biotech teams an intelligent, connected operating layer for moving assets from development strategy to the clinic.
Our approach
Keep material facts, assumptions, interpretations, and decisions reviewable and traceable to evidence as the development program changes.
Domain expertise meets technical innovation
Tomas VanAdvisor15+ years of clinical operations experience
Cadence ChenCEOBuilt enterprise systems at Amazon